Rethinking clinical trials for cytostatic drugs
- 1 July 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (7) , 540-545
- https://doi.org/10.1038/nrc1124
Abstract
The failure of many cytostatic agents in Phase III clinical trials for treatment of common cancers has led researchers to question current approaches to trial development. Recent studies offer some clues as to what is wrong with two particular aspects of clinical trial design--survival as an end point and simultaneous combination with cytotoxic chemotherapy--and indicate possible alternatives.Keywords
This publication has 21 references indexed in Scilit:
- Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2003
- ErbB2 Pathways in Heart and Neural DiseasesTrends in Cardiovascular Medicine, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical TrialsJournal of Clinical Oncology, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trialsSeminars in Oncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000